Overture Orthopaedics is celebrating a significant sales achievement, having sold $1 million worth of its OvertureTi Knee Resurfacing System.

OvertureTi Knee Resurfacing System implants are designed specifically as an alternative to both arthroplasty and biological repair options for early osteoarthritis and focal cartilage lesion treatment. The system is composed of femoral and tibial implants that partially replace the knee’s articular surfaces. The implants have sizing options that allow surgeons to replace only the diseased or damaged joint region while preserving healthy native cartilage and soft tissue. The procedure is referred to as Focalplasty.

“As a cartilage preservation doctor, seeing my younger patients getting older, getting more arthritic while wanting to maintain their active lifestyles, techniques such as meniscus transplantation and osteochondral allograft are less successful; so we need other options such as metallic implants to help us resurface joints and be a key part of our cartilage repair algorithm,” said Dr. Bert Mandelbaum, professor and vice chair of the Orthopaedic Surgery Department at Cedars-Sinai, associate chief medical officer of Major League Soccer, and team physician of U.S. Soccer. “I think the Overture solution gives us an ideal alternative solution to deficits of cartilage and bone in the osteoarthritic situation where the knee begins showing signs of a catabolic state. Overture will continue gaining traction as a solution to address this growing subset of patients.”

With an increasingly active patient population, the number of cartilage restoration surgeries performed annually exceeds 300,000 and is growing each year. A 2021 paper on chondral knee lesions in the Journal of Bone and Joint Surgery by Dekker et al., notes that current surgical and biological options for treating isolated cartilage defects present significant cost and complexity challenges for patients and surgeons—i.e., inconsistent healing, donor site morbidity, and degradation over time. According to a study by McCormick et al. that focused on trends in U.S. articular cartilage lesion treatment, some procedures such as chondrocyte implantation can cost as much as $83,073 due to multi-stage surgeries, laboratory processing, associated care episodes, and societal considerations.

“There exists a large and growing group of patients between the ages of 35 and 65 who present with symptomatic articular cartilage lesions and early osteoarthritis of the knee,” Overture Orthopaedics CEO James Young Kim stated. “These patients are often deemed inappropriate for partial and total knee replacements and are increasingly seeking alternatives to early joint reconstruction, preferring joint preservation options. However, the efficacy of current biologic cartilage repair strategies in joint preservation remains questionable due to long term durability, progressive knee joint catabolism, and prolonged recovery with inconsistent results in middle aged and older patients. Overture’s solution addresses this group with a bridging procedure to delay joint reconstruction so that patients can maintain their active lifestyles for a longer period of their lives.”

Overture’s technologically advanced, biocompatible implants have baseplates that are 3D printed, porous titanium to promote solid fixation; articulating surfaces for the femoral and tibial components are clinically proven titanium nitride and over-molded highly cross-linked Vitamin E treated polyethylene, respectively. The implants are a fraction of the cost of biological options, according to the company.

The OvertureTi Knee Resurfacing System is 510(k) cleared by the U.S. Food and Drug Administration. All instrumentation is sterile-packed for streamlined, single-use efficiency in the operating room.

Overture Orthopaedics is a privately held medical device company providing sports medicine and orthopadic surgeons with specially designed implants to relieve pain and dysfunction associated with articular cartilage lesions, osteochondral defects, and early osteoarthritis. The company claims its solutions raise the standard of care in joint preservation by providing state-of-the-art surgical tools that streamline O.R. use, reduce global care costs, and enhance outcomes.